Generate Biomedicines, Inc. (GENB)
Nasdaq: GENB · Pharmaceutical Preparations · filing with the SEC since 2025
Who runs Generate Biomedicines, Inc.
Officers and directors as they report to the SEC on Forms 3, 4 and 5, named as filedChief executive, as filed
Nally Michael
Chief Executive Officer. First filing Feb 2026, latest Mar 6, 2026, 1 filing in all.
Officers reporting now
7
of 15 people with a filing in the last fifteen months
Directors reporting now
8
15 people on the record since 2026
Officerssales are open-market, Nov 4, 2025 to Nov 4, 2026
| Name | Title as filed | First filing | Latest filing | Sales, 12 months |
|---|---|---|---|---|
| Nally Michael | Chief Executive Officer | Feb 2026 | Mar 6, 2026 | none |
| Silvers Jason | President & CFO | Feb 2026 | Mar 2, 2026 | none |
| Grigoryan Gevorg | Chief Technology Officer | Feb 2026 | Mar 2, 2026 | none |
| Grous Beth | Chief People Officer | Feb 2026 | Mar 2, 2026 | none |
| Lee Laurie Anne | Chief Medical Officer | Feb 2026 | Mar 2, 2026 | none |
| Martin Sean | Chief Legal Officer & GC | Feb 2026 | Mar 2, 2026 | none |
| Khakoo Aarif | Chief Scientific Officer | Feb 2026 | Feb 26, 2026 | none |
Directorssales are open-market, Nov 4, 2025 to Nov 4, 2026
| Name | Role | First filing | Latest filing | Sales, 12 months |
|---|---|---|---|---|
| Arnold Frances | director | Feb 2026 | Nov 4, 2026 | 2 · $200,000 |
| Afeyan Noubar | director | Feb 2026 | Mar 2, 2026 | none |
| Bancel Stephane | director | Feb 2026 | Mar 2, 2026 | none |
| Fanucci Marsha | director | Feb 2026 | Mar 2, 2026 | none |
| Mendillo Jane L | director | Feb 2026 | Mar 2, 2026 | none |
| Parker Paul Gray | director | Feb 2026 | Mar 2, 2026 | none |
| Simonian Nancy A | director | Feb 2026 | Mar 2, 2026 | none |
| Vessey Rupert | director | Feb 2026 | Mar 2, 2026 | none |
Owners of more than 10% of a classsales are open-market, Nov 4, 2025 to Nov 4, 2026
A person is listed as reporting now after a filing in the last fifteen months. The record shows when someone last filed; it does not say why they stopped. Each name links to the filings on sec.gov.